Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has earned an average recommendation of “Hold” from the six analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $12.00.
A number of research firms have issued reports on XERS. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Barclays raised their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th.
Check Out Our Latest Analysis on Xeris Biopharma
Xeris Biopharma Stock Performance
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. On average, sell-side analysts anticipate that Xeris Biopharma will post 0.07 EPS for the current year.
Insider Transactions at Xeris Biopharma
In other news, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $8.01, for a total transaction of $133,494.66. Following the transaction, the insider owned 1,144,462 shares in the company, valued at approximately $9,167,140.62. The trade was a 1.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Johnson sold 15,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $91,350.00. Following the transaction, the director directly owned 683,083 shares of the company’s stock, valued at $4,159,975.47. This represents a 2.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 254,832 shares of company stock worth $1,937,915. 4.35% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Xeris Biopharma
A number of institutional investors have recently added to or reduced their stakes in XERS. Cetera Investment Advisers raised its holdings in Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after acquiring an additional 1,735 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Xeris Biopharma by 6.5% in the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after purchasing an additional 2,351 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after purchasing an additional 2,494 shares during the period. Finally, Kestra Advisory Services LLC bought a new position in Xeris Biopharma in the fourth quarter worth $25,000. 42.75% of the stock is owned by institutional investors and hedge funds.
Xeris Biopharma Company Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
- Five stocks we like better than Xeris Biopharma
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
